"What this means is that, were Theranos to report unusual lab test results on a patient, that patient’s physician may choose to retest the patient with a different clinical lab, or might even split samples between Theranos and the incumbent lab serving that physician’s office. The physician, and the incumbent lab, would then be in a position to critically assess the accuracy—or inaccuracy—of the lab test results reported by Theranos."
Yep. The rubber is going to meet the road and Theranos will be humbled. Get ready for their bloated market cap to pop.
